天香丹治疗冠状动脉粥样硬化性心脏病秽浊痰阻证患者的临床疗效观察

Clinical efficacy observation on Tianxiangdan treating coronary heart disease patients with phlegm blocking syndrome

目的:观察天香丹治疗冠状动脉粥样硬化性心脏病(以下简称冠心病)秽浊痰阻证患者临床疗效及对血清中基质金属蛋白酶9(MMP-9)和基质金属蛋白酶抑制剂1(TIMP-1)表达水平的影响,探讨天香丹防治冠心病的可能机制。方法:收集符合纳入标准冠心病稳定型心绞痛患者100例,随机分为对照组和治疗组各50例,对照组予西医基础药物(阿司匹林肠溶片和阿托伐他汀钙片),治疗组予天香丹和西医基础药物。两组分别给予相应治疗4周,酶联免疫双抗夹心(ELISA)法检测两组患者治疗前后血清MMP-9和TIMP-1含量。结果:与对照组比较,治疗组可明显减轻冠心病患者心绞痛临床症状以及改善心电图疗效(P<0.05)。与本组治疗前比较,两组治疗后血清中MMP-9表达显著下调(P<0.05),TIMP-1表达显著上调(P<0.05)。结论:天香丹可能通过抑制MMP-9的表达,促进TIMP-1的表达,发挥稳定粥样硬化斑块的作用。

Objective: To observe the effects of Tianxiangdan(TXD) on clinical efficacy in patients with coronary heart disease and serum inflammatory factor matrix metalloproteinase-9(MMP-9) and the tissue inhibitors of matrix metalloproteinase-1(TIMP-1), explore the possible mechanism of TXD in prevention and treatment of coronary heart disease. Methods: A total of 100 patients with stable angina pectoris of coronary heart disease were randomly divided into treatment group and control group, 50 cases in each group. The control group was given basic western medicine(aspirin enteric coated tablets and atorvastatin calcium tablets), while the treatment group was given Tianxiangdan and basic western medicine. The two groups were given corresponding treatment for 4 weeks. The contents of serum MMP-9 and TIMP-1 were detected by enzyme-linked immunosorbent assay(ELISA) before and after treatment. Results: Compared with the control group, the treatment group can significantly reduce the clinical symptoms of angina pectoris and improve the clinical ischemic manifestations of ECG in patients with coronary heart disease, Compared with before treatment, both groups could down regulate the expression of MMP-9 and up regulate the expression of TIMP-1 after treatment(P<0.05).Conclusion: TXD may play a role in stabilizing atherosclerotic plaque by inhibiting the expression of MMP-9 and promoting the expression of TIMP-1.